Author

M. George

Observed names: Molly George, Molly S. George, Molly Sarah George

Institutions: Rutgers, The State University of New Jersey, Guy's Hospital, King's College London, Rutgers Cancer Institute, University of Pennsylvania

Observed institutions: Rutgers, The State University of New Jersey, Guy's Hospital, King's College London, University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Tamworth Hospital, Rutgers Cancer Institute, University of Pennsylvania

ORCID: 0000-0002-0547-813X

Observed ORCID: 0000-0002-0547-813X

OpenAlex ID: A5000692612

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study

2023 · Sophie Papa, Antonella Adami, et al. · Journal for ImmunoTherapy of Cancer · 60

Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner

2024 · Caroline M. Hull, Daniel Larcombe-Young, et al. · Molecular Therapy · 37

Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function

2023 · Molly S. George, Jenifer Sanchez, et al. · iScience · 16

Pos0071 Immunomodulatory Treatment and Immune Responses to Covid-19 Booster Shots in Patients With Autoimmune Rheumatic Diseases: Results From the Covid-19 Vaccine Response in Rheumatology Patients (cover) Study

2024 · J.R. Curtis, A. Mudano, et al. · Annals of the Rheumatic Diseases · 2

Op0150 What Is the Role of Temporal Artery Biopsy in Giant Cell Arteritis Fast-track Pathways When Temporal Artery Ultrasound Is Negative?

2020 · A. Sachdev, S. Dubey, et al. · Annals of the Rheumatic Diseases · 1

Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications

2020 · D. Watrous, George E. Parris, et al. · Arthritis & Rheumatism · 1

437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)

2024 · M. George, J-S. Frenel, et al. · Annals of Oncology

1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

2023 · D. Olson, E.E. Dumbrava, et al. · Annals of Oncology

P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

2023 · E. Dumbrava, D. Olson, et al. · Annals of Oncology

Thrombo-embolic events in geriatric oncology patients; a rural cancer centre perspective

2012 · S.R. Vemula⁎, M. George, et al. · Journal of Geriatric Oncology

Works count: 10

Citation count: 117

H-index: 3

I10-index: 3